151252-80-1

Basic information

• Product Name: N-[(S)-(-)-1-PHENYLETHYL]IMIDAZOLE-1-CARBOXAMIDE
• Synonyms: N-[(S)-(-)-1-PHENYLETHYL]IMIDAZOLE-1-CARBOXAMIDE;(S)-N-(1-Phenylethyl)-1H-iMidazole-1-carboxaMide
• CAS NO: 151252-80-1
• Molecular Formula: C12H13N3O
• Molecular Weight: 215.25
• Product Categories: Chiral Reagents
• Mol File: 151252-80-1.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Density: 1.16±0.1 g/cm3(Predicted)
• PKA: 9.21±0.46(Predicted)
• CAS DataBase Reference: N-[(S)-(-)-1-PHENYLETHYL]IMIDAZOLE-1-CARBOXAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-[(S)-(-)-1-PHENYLETHYL]IMIDAZOLE-1-CARBOXAMIDE(151252-80-1)
• EPA Substance Registry System: N-[(S)-(-)-1-PHENYLETHYL]IMIDAZOLE-1-CARBOXAMIDE(151252-80-1)

Safety Data

• Hazardous Substances Data: 151252-80-1(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 151252-80-1 differently. You can refer to the following data:
1. N-[(S)-(-)-1-PHENYLETHYL]IMIDAZOLE-1-CARBOXAMIDE is a useful synthetic intermediate
2. A useful synthetic intermediate.

Upstream product

• 2627-86-3 (S)-1-phenyl-ethylamine 
• 530-62-1 1,1'-carbonyldiimidazole 

Downstream Products

• 1228342-28-6 (S)-4-(2,4-dihydroxyphenyl)-N-(1-phenylethyl)-piperidine-1-carboxamide 

Relevant articles and documents

Process Development and Good Manufacturing Practice Production of a Tyrosinase Inhibitor via Titanium-Mediated Coupling between Unprotected Resorcinols and Ketones

A concise and economically attractive process for the synthesis of a novel tyrosinase inhibitor has been developed and implemented on a multikilogram scale under GMP. A major achievement to the success of the process is the development of a direct coupling between free resorcinol and ketone. First developed under basic conditions, this coupling has been turned to a novel titanium(IV) mediated process allowing good selectivity, easy isolation, and high atom efficiency. Other key steps feature an alkene reduction by palladium catalyzed transfer hydrogenation and a urea formation using N,N′-disuccinimidyl carbonate as the carbonyl source. This route allowed us to produce kilogram batches of the candidate to support preclinical and clinical studies.